Sagar D Sardesai, MBBS
Academic Title: Associate Professor in the College of Medicine
Research Program: Cancer Control
About Me
More info forI am a breast medical oncologist and researcher who joined the Division of Medical Oncology at The Ohio State University in 2016 after completing my fellowship training in hematology and oncology at Indiana University (IU). I have a proven track record of academic and clinical excellence. I earned my medical degree in Mumbai, India and my master’s degree in public health at The University of Texas Health Science Center in Houston. I then completed a general internal medicine internship at the University of Buffalo School of Medicine – State University of New York before embarking on my fellowship training at IU. I am a member of the Cancer Control Program at the OSUCCC – James. My research involves identifying predictive biomarkers in BRCA gene-mutated tumors and triple-negative breast cancers. I also have research interests in women who are at high risk for breast and ovarian cancers, and in the correlation between breast density and obesity in healthy women. I currently serve as the co-medical director of the high-risk breast program. Additionally, I have published manuscripts in scientific journals and presented original articles at national conferences. I am a reviewer for multiple medical journals and a member of several medical organizations, including the American Society of Clinical Oncology, American College of Hematology and American Medical Association. Working at the OSUCCC – James gives me the resources and technology to provide the best care possible to my patients. I try and educate each patient about their condition, so they can make active decisions regarding treatment. At The James, we define cancer by its biologic and genetic makeup, knowing that it’s different in each person. Through collaboration and cutting-edge technology, we create improved outcomes, faster responses, fewer side effects and more hope for cancer patients.
Clinical Expertise
More info for- Ovarian Cancers
- Genes, BRCA1
- Genes, BRCA2
- Breast Cancer
Where I See Patients
More info forStefanie Spielman Comprehensive Breast Center
1145 Olentangy River Road Columbus, Ohio 43212 800-293-5066 Location InformationEducation & Training
More info forFellowship - Hematology & Oncology
- Indiana University Hospital
550 University Blvd, Indianapolis, IN
Internship - Internal Medicine
- State University of NY Health Science Center/Brooklyn
PO Box 30046, Brooklyn, NY
Residency - Internal Medicine
- State University of NY Health Science Center/Brooklyn
PO Box 30046, Brooklyn, NY
Medical School
- Topiwala National Medical College
Maharashtra University of Health Sciences, Mumbai
Graduate - Epidemiology
- University of Texas HSC School of Public Health
PO Box 20186, Houston, TX
- Indiana University Hospital
Academic Office & Contact Information
More info forAcademic Office:
Lincoln Tower 1335
1800 Cannon Dr
Columbus, Ohio 43210Email:
sagar.sardesai@osumc.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forSeptember 12, 2024Association Between Inflammatory Dietary Pattern and Mammographic Features.
Azam S, Asad S, Chitnis SD, Collier KA, Kensler KH, Sudheendra P, Pariser A, Romanos-Nanclares A, Eliassen AH, Sardesai S, Heine J, Tabung FK, Tamimi RM, Stover DG
J Nutr
June 19, 2024The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer.
Johnson KCC, Ni A, Quiroga D, Pariser AC, Sudheendra PK, Williams NO, Sardesai SD, Cherian M, Stover DG, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R
NPJ Breast Cancer
June 1, 2024Potential Therapeutic Role of Respiratory Muscle Training in Dyspnea Management of Cancer Survivors: A Narrative Review.
Vainshelboim B, Sardesai SD, Bhammar D
World J Oncol
June 1, 2024Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
Sukumar JS, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover DG, Gatti-Mays M, Pariser A, Sudheendra P, George MA, Lustberg M
Cancer Med
May 30, 2024Chemotherapy-induced gut microbiome disruption, inflammation, and cognitive decline in female patients with breast cancer.
Otto-Dobos LD, Grant CV, Lahoud AA, Wilcox OR, Strehle LD, Loman BR, Adarkwah Yiadom S, Seng MM, Halloy N, Russart KLG, Carpenter KM, Dawson E, Sardesai SD, Williams NO, Gatti-Mays ME, Stover DG, Sudheendra PK, Wesolowski R, Kiecolt-Glaser JK, Bailey MT, Andridge RR, Pyter LM
Brain Behav Immun
November 22, 2023Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients.
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi CL, Ruddy KJ, Cathcart-Rake E, Trovato S, Dulmage B
Support Care Cancer
October 14, 2023Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls.
Johnson KC, Grimm M, Sukumar J, Schnell PM, Park KU, Stover DG, Jhawar SR, Gatti-Mays M, Wesolowski R, Williams N, Sardesai S, Pariser A, Sudheendra P, Tozbikian G, Ramaswamy B, Doto D, Cherian MA
Breast
September 4, 2023Depression, Inflammation, and Intestinal Permeability: Associations with Subjective and Objective Cognitive Functioning throughout Breast Cancer Survivorship.
Madison AA, Andridge R, Kantaras AH, Renna ME, Bennett JM, Alfano CM, Povoski SP, Agnese DM, Lustberg M, Wesolowski R, Carson WE, Williams NO, Reinbolt RE, Sardesai SD, Noonan AM, Stover DG, Cherian MA, Malarkey WB, Kiecolt-Glaser JK
Cancers (Basel)
June 24, 2023The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.
Johnson KCC, Goldstein D, Tharakan J, Quiroga D, Kassem M, Grimm M, Miah A, Vargo C, Berger M, Sudheendra P, Pariser A, Gatti-Mays ME, Williams N, Stover D, Sardesai S, Wesolowski R, Ramaswamy B, Tozbikian G, Schnell PM, Cherian MA
Oncol Ther
March 14, 2023Hyperinsulinemic and Pro-Inflammatory Dietary Patterns and Metabolomic Profiles Are Associated with Increased Risk of Total and Site-Specific Cancers among Postmenopausal Women.
Jin Q, Shi N, Lee DH, Rexrode KM, Manson JE, Balasubramanian R, Zhang X, Neuhouser ML, Lopez-Pentecost M, Thomson CA, Zick SM, Felix AS, Stover DG, Sardesai SD, Esnakula A, Mo X, Clinton SK, Tabung FK
Cancers (Basel)
January 1, 2023Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams NO, Quiroga D, Johnson C, Brufsky A, Chambers M, Bhattacharya S, Patterson M, Sardesai SD, Stover D, Lustberg M, Noonan AM, Cherian M, Bystry DM, Hill KL, Chen M, Phelps MA, Grever M, Stephens JA, Ramaswamy B, Carson WE, Wesolowski R
Ther Adv Med Oncol
November 14, 2022Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.
Asad S, Damicis A, Heng YJ, Kananen K, Collier KA, Adams EJ, Kensler KH, Baker GM, Wesolowski R, Sardesai S, Gatti-Mays M, Ramaswamy B, Eliassen AH, Hankinson SE, Tabung FK, Tamimi RM, Stover DG
Breast Cancer Res
October 5, 2022Typhoid Vaccine Does Not Impact Feelings of Social Connection or Social Behavior in a Randomized Crossover Trial Among Middle-Aged Female Breast Cancer Survivors.
Madison AA, Way B, Ratner K, Renna M, Andridge R, Peng J, Rosie Shrout M, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, VanDeusen JB, Williams NO, Sardesai SD, Noonan AM, Reinbolt RE, Stover DG, Cherian MA, Malarkey WB, Kiecolt-Glaser JK
Brain Behav Immun
July 13, 2022Distress Disorder Histories Relate to Greater Physical Symptoms Among Breast Cancer Patients and Survivors: Findings Across the Cancer Trajectory.
Renna ME, Shrout MR, Madison AA, Lustberg M, Povoski SP, Agnese DM, Reinbolt RE, Wesolowski R, Williams NO, Ramaswamy B, Sardesai SD, Noonan AM, VanDeusen JB, Stover DG, Cherian M, Malarkey WB, Di Gregorio M, Kiecolt-Glaser JK
Int J Behav Med
July 10, 2022Living with Advanced Breast Cancer: A Descriptive Analysis of Survivorship Strategies.
Grimm M, Radcliff L, Giles M, Nash R, Holley E, Panda S, Brophy L, Williams N, Cherian M, Stover D, Gatti-Mays ME, Wesolowski R, Sardesai S, Sudheendra P, Reinbolt R, Ramaswamy B, Pariser A
J Clin Med
May 11, 2022Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J
Breast Cancer Res Treat
April 1, 2022Breast cancer survivors' typhoid vaccine responses: Chemotherapy, obesity, and fitness make a difference.
Kiecolt-Glaser JK, Renna M, Peng J, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, VanDeusen JB, Williams NO, Sardesai SD, Noonan AM, Reinbolt RE, Stover DG, Cherian MA, Malarkey WB, Andridge R
Brain Behav Immun
February 23, 2022Delay Discounting as a Potential Therapeutic Target for Weight Loss in Breast Cancer Survivors.
Sukumar JS, Vaughn JE, Tegge A, Sardesai S, Lustberg M, Stein J
Cancers (Basel)
January 31, 2022Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors.
Quick AM, Hundley A, Evans C, Stephens JA, Ramaswamy B, Reinbolt RE, Noonan AM, Van Deusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Faubion SS, Loprinzi CL, Lustberg MB
J Clin Med
January 1, 2022Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer.
Datta J, Willingham N, Manouchehri JM, Schnell P, Sheth M, David JJ, Kassem M, Wilson TA, Radomska HS, Coss CC, Bennett CE, Ganju RK, Sardesai SD, Lustberg M, Ramaswamy B, Stover DG, Cherian MA
Front Oncol
November 1, 2021Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.
Sardesai SD, Thomas A, Gallagher C, Lynce F, Ottaviano YL, Ballinger TJ, Schneider BP, Storniolo AM, Bauchle A, Althouse SK, Perkins SM, Masters AR, Stratford RE, Dong Z, Liu JY, Zhang JT, Miller KD
Clin Cancer Res
October 1, 2021Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience.
Rinehardt H, Kassem M, Morgan E, Palettas M, Stephens JA, Suresh A, Ganju A, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Cherian M, Prieto Eibl MDPG, Miah A, Alnahhas I, Giglio P, Puduvalli VK, Ramaswamy B, Williams N, Noonan AM
Adv Psychosom Med
September 1, 2021Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA
Ann Oncol
April 22, 2021Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS, ASCENT Clinical Trial Investigators
N Engl J Med
January 1, 2021A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study.
Zvinovski F, Stephens JA, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Mehta L, Foraker R, Gulati M, Lustberg M, Quick AM
J Oncol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Sardesai has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- AstraZeneca
- Gilead Sciences
- Stemline Therapeutics
Patient Comments
I can't believe--and neither can friends--how much time I get for an appointment. Such care and concern. I have been blessed with Dr. Sardesai and Jaimie and staff.
Excellent doctor very kind and compassionate
He is an excellent oncologist!
Dr Sardesi is the best. He answers all my concerns.
I love Dr. Sardesai. I'm praying Anthem can come to an ageeement
Dr S was kind, informative and caring.
I was given all the time I needed for my questions. I was meet with great compassion and care. Additional evidence bases information was provided to allow meTo be more informed about future concern and risk factors. Dr S is top notch!!!!!
My doctor is an excellent caregiver.
I have always felt that good attention is provided and I never feel rushed.
Excellent and thorough care.
Was very impressed with the variety of topics addressed and what to expect as far as the next step. Dr. Sardesai was very knowledgeable and personable. He also took the time to listen and to ask if I had any questions or concerns along the way.
Best doctor evier
I deeply value the care and concern Dr Sardesai has for me and his other patients. He takes his time with me, answers my questions and remembers my issues and questions from previous visits. This is greatly appreciated.
We were so impressed and comforted with our visit with Dr. Sardesai!. Not only Is he extremely knowledgeable, made it easy to understand but his positivity and compassion made us come out feeling better than we've felt in weeks!
Only my first visit but I was very impressed with staff
Always great
I have had good care with Dr Sardesai.My former doctor resigned.I drive 65 miles each way. Sometimes it is a long day.I have had no treatments. I take a pill and tumor is gone, thankfully.I am very pleased.
The Dr was very nice, took his time and explained everything!
Very thorough in answering all my questions in an honest and easy to understand manner.
Never close to being on time
Dr. Sardesai and his team always put the patient first
Always answers my questions about whatever I'm concerned about
Never have I been treated so good and was kept informed during stay. Best health care ever.
Was very much concerned and helpful.
I have been a patient here for over 6 years. The staff is informative, kind and courteous.
Dr Sardesai never rushes you and always answers all questions. And provides good information on questions.
Excellent caregivers